To know more about this research:

Digest

Scientific Article

The overall goal of this event is to highlight examples from international funding entities that are either already piloting or considering implementing different models to allocate research funds, with a particular emphasis on the partial randomisation process, and highlight the perspective of researchers on this topic.

The session will end with a roundtable discussion featuring the views from researchers hosted by Portuguese institutions on whether partial randomisation is an appropriate alternative to the current peer review process.  

To know more about this research:

Digest

Scientific Article

Funded by the MCSA & Citizens action - RAISE is built around a concept of co-creation that will blend Researchers at Schools (RAS) activities with European Researchers’ Nights (ERN) public events over the next two years.

In the USA, rTMS was cleared by the Food and Drug Administration (FDA) in 2008 to treat patients suffering from treatment resistant depression, or in other words, patients who do not respond to standard antidepressants. It has since been approved or recommended in several other countries. The main advantage of rTMS is that it is a non-invasive, drug-free, and safe alternative treatment that really works: up to half of the patients for whom other antidepressant strategies have not worked will respond to rTMS.